Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01), Zacks reports.
Eupraxia Pharmaceuticals Trading Down 2.3 %
Shares of NASDAQ EPRX opened at $3.82 on Friday. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $4.48. The stock has a 50 day moving average of $3.49 and a two-hundred day moving average of $3.10. The stock has a market cap of $136.17 million and a P/E ratio of -5.31.
Analyst Ratings Changes
Separately, Craig Hallum initiated coverage on Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They issued a “buy” rating and a $12.00 price objective for the company.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- How to buy stock: A step-by-step guide for beginners
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Stock Sentiment Analysis: How it Works
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
